Search results
Results from the WOW.Com Content Network
The European Society of Cardiology (ESC), [25] and National Institute for Health and Care Excellence (NICE) [27] guidelines recommend that if the patient has a CHA 2 DS 2-VASc score of 2 and above, oral anticoagulation therapy (OAC) with a vitamin K antagonist (VKA, e.g. warfarin with target INR of 2-3) or one of the direct oral anticoagulant ...
Similar to the NINCDS-ADRDA Alzheimer's Criteria are the DSM-IV-TR criteria published by the American Psychiatric Association. [3] At the same time the advances in functional neuroimaging techniques such as PET or SPECT that have already proven their utility to differentiate Alzheimer's disease from other possible causes, [4] have led to proposals of revision of the NINCDS-ADRDA criteria that ...
Activated clotting time (ACT), also known as activated coagulation time, is a test of coagulation. [1] [2]The ACT test can be used to monitor anticoagulation effects, such as from high-dose heparin before, during, and shortly after procedures that require intense anticoagulant administration, such as cardiac bypass, interventional cardiology, thrombolysis, extra-corporeal membrane oxygenation ...
Named lectures include the Sir Arthur Hurst lecture and the Sir Francis Avery Jones BSG Research medallist. Recent presidents have been Hermon Dowling (1996–1997), Chris Hawkey (2010), Jon Rhodes (2011–12), Ian Gilmore (2013–14), Ian Forgacs (2014–16), Martin Lombard (2016–18), Cathryn Edwards (2018–20), Alastair McKinlay (2020-22 ...
Therefore, early and accurate diagnosis of dementia and staging can be essential to proper clinical care. Without the ability to reliably assess dementia across the board, the misuse of anti-dementia compounds could have negative consequences, such as patients receiving the wrong medication, or not receiving treatment in the early stages of ...
Alzheimer's disease (AD) is a neurodegenerative disease and the most common cause of dementia; it usually occurs in old age. Familial Alzheimer's disease (FAD or EOFAD for early onset) is an inherited and uncommon form of AD. Familial AD usually strikes earlier in life, defined as before the age of 65.
In a double-blind trial of the humanised monoclonal antibody solanezumab (n = 2042), sixteen patients (11 taking the drug, 5 taking a placebo), or 0.78% developed ARIA-E. A further 7 patients developed ARIA-E during an open-label extension of the trial. [4] The effect of ARIA-E depends on the severity and location of the edema.
The scale was used as an outcome measure of the first randomised controlled trial of an intervention to alleviate feeding difficulty [7] and has been used as an outcome measure in a national study of feeding difficulty in older people with dementia in Canada; [8] In this study it was shown that a 1-unit change in the EdFED score is equivalent ...